Maiyata

Maiyata is a biotechnology company focused on developing therapies to combat aging and age-related diseases. Co-founded by Eric Verdin, a prominent figure in geroscience and the head of the Buck Institute for Research on Aging, the company aims to translate fundamental biological discoveries into clinical applications. Maiyata's research centers on cellular rejuvenation, epigenetic reprogramming, and metabolic health, specifically targeting pathways that govern the aging process. The company is currently in the pre-clinical stage, building a platform to identify and validate novel therapeutic targets. By addressing the root causes of cellular decline, Maiyata seeks to extend human healthspan and treat a variety of chronic conditions associated with growing older.